-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CC-95775 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CC-95775 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CC-95775 in Solid Tumor Drug Details: CC-95775 (FT-1101) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tremelimumab in Dysgerminoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tremelimumab in Dysgerminoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tremelimumab in Dysgerminoma Drug Details: Tremelimumab (Imjudo) is a human monoclonal monospecific...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vorolanib in Wet (Neovascular / Exudative) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vorolanib in Wet (Neovascular / Exudative) Macular Degeneration report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vorolanib in Wet (Neovascular / Exudative) Macular...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lurbinectedin in Metastatic Biliary Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lurbinectedin in Metastatic Biliary Tract Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lurbinectedin in Metastatic Biliary Tract Cancer Drug Details: Lurbinectedin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lurbinectedin in Neuroendocrine Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lurbinectedin in Neuroendocrine Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lurbinectedin in Neuroendocrine Carcinoma Drug Details: Lurbinectedin (Zepzelca) is a synthetic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lurbinectedin in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lurbinectedin in Esophageal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lurbinectedin in Esophageal Cancer Drug Details: Lurbinectedin (Zepzelca) is a synthetic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lurbinectedin in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lurbinectedin in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lurbinectedin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lurbinectedin in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lurbinectedin in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lurbinectedin in Triple-Negative Breast Cancer (TNBC) Drug Details: Lurbinectedin...
-
Product Insights
NewNet Present Value Model: Jazz Pharmaceuticals Plc’s JZP-898
Empower your strategies with our Net Present Value Model: Jazz Pharmaceuticals Plc's JZP-898 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Jazz Pharmaceuticals Plc’s JZP-815
Empower your strategies with our Net Present Value Model: Jazz Pharmaceuticals Plc's JZP-815 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.